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Background: The purpose of this study was to evaluate the association between blood manganese levels and the
prevalence of chronic diseases in the Korean population.
Methods: This was a cross-sectional study based on the Korean National Health and Nutrition Examination Survey
(KNAHNES). The study included 3996 participants 20 years of age or older whose blood manganese levels had been
measured. The participants were also evaluated for the presence of five chronic diseases: diabetes, renal dysfunction,
hypertension, ischemic heart disease, and stroke.
Results: Blood manganese levels were significantly lower in the diabetes group compared with the non-diabetes
group (1.26 ± 0.02 vs. 1.35 ± 0.01 μg/dL; p = 0.001) and the renal dysfunction group compared with those with
normal renal function (1.28 ± 0.03 vs. 1.35 ± 0.01 μg/dL; p = 0.04). There was no significant association between
blood manganese levels and the presence of ischemic heart disease or stroke. A multivariate logistic regression
analysis adjusted for age, sex, and body mass index was performed; the odds ratio was 0.652 (95% CI: 0.46–0.92) for
diabetes and 0.589 (95% CI: 0.39–0.88) for renal dysfunction when comparing the higher quartiles (Q2-4) with the
lowest quartile (Q1) of blood manganese level. The prevalence of diabetes was 7.6% in Q1 and 5.3% in Q2-4
(p = 0.02). Similarly, the prevalence of renal dysfunction was 6.8% in Q1, compared with 4.6% in Q2-4 (p = 0.02).
Conclusion: The prevalence of diabetes and renal dysfunction increased in participants with low blood manganese
levels, suggesting that blood manganese may play a role in glucose homeostasis and renal function.
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Manganese (Mn) is an essential trace metal with insuffi-
cient intake in virtually all diets. It has been reported that
Mn is involved in normal immune functions, regulation of
blood sugar and cellular energy, and the defense mecha-
nisms against free radicals [1,2]. Experimentally induced
Mn deficiency caused a number of detrimental effects, such
as impaired bone formation, abnormal glucose tolerance,
low levels of high-density lipoprotein (HDL) cholesterol,
and skin abnormalities in both animals and humans [3].* Correspondence: imkidney@catholic.ac.kr
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reproduction in any medium, provided the orConversely, excess occupational inhalation of Mn may be
neurotoxic to humans, producing effects such as psychosis
and Parkinsonism. Mn deficiency and intoxication are both
associated with adverse metabolic and neuropsychiatric ef-
fects [4,5]. Nevertheless, little is known about the optimal
blood Mn levels for maintaining homeostasis in humans.
One study found that Mn inhalation in adult animal
models markedly down-regulated the gene expression of
proteins critical to inflammatory responses or possessing
pro-oxidant properties (e.g. tumor growth factor (TGF)-β
and neuronal nitric oxide synthase (nNOS)) [6]. These
results suggested that a certain amount of Mn exposure
may attenuate the inflammatory response to stressful
environments. In contrast, Mn is an essential cofactor for
metalloenzyme superoxide dismutase, which protects cells. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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strated that Mn deficiency and the resultant decrease
in manganese superoxide dismutase (MnSOD) activity
caused heart mitochondria to be more sensitive to
in vivo oxidative damage [7]. This study proposed that
subclinical Mn deficiency might also contribute to ex-
cess oxidative stress.
Oxidative stress and inflammation are the main patho-
physiology behind most chronic diseases. Therefore, we
hypothesized that blood Mn levels could be related to
the prevalence of chronic diseases. We conducted a
cross-sectional analysis on the associations of blood Mn
level with five chronic diseases (diabetes, renal dysfunc-
tion, hypertension, ischemic heart disease, and stroke) in
a representative sample of the adult Korean population




The KNHANES was performed to examine the general
health and nutritional status of the civilian, non-
institutionalized Korean population. KNHANES is a
cross-sectional and nationally representative survey com-
posed of a health questionnaire, a health examination, and
a nutrition survey. The fourth KNHANES (KNHANES
IV) was conducted from 2007 to 2009 using a stratified,
multistage probability sampling design. We used data
from the second (2008) to third year (2009) of the
KNHANES IV. Of the 8641 individuals who partici-
pated during this time, we analyzed those who were
20 years of age or older and tested for blood Mn. We
excluded participants who were pregnant or had miss-
ing values and yielded a final sample size of 3996
adults. The Catholic University of Korea Incheon St.
Mary’s Hospital Institutional Review Board and the
Korea Centers for Disease Control and Prevention ap-
proved the study protocol, and written informed con-
sent was obtained from all participants before the
study began.
Laboratory measurements
Blood Mn was measured using whole blood at the Neodin
Medical Institute (certified by the Korean Ministry of
Health and Welfare) in Seoul, Korea, following a stan-
dardized protocol. Blood Mn was analyzed by graphite
furnace atomic absorption spectrometry with Zeeman
background correction (Perkin Elmer AAS800, Perkin
Elmer, Turku, Finland). The limit of detection was 0.016
μg/dL for blood Mn. For internal quality assurance and
control, standard reference materials were obtained
from Bio-Rad (Lyphochek® Whole Blood Metals Con-
trol). The inter-assay coefficients of variation ranged
from 0.95% to 4.82% for blood Mn samples (referencevalues were 0.98, 1.18, 2.46, and 3.28 μg/dL). During the
survey, overnight fasting venous blood samples were
collected. The collected blood samples were properly
processed, refrigerated, and transported in cold storage
to the Neodin Medical Institute in Seoul, Korea.
Chronic diseases
Diabetes was defined as having one of the following: a
fasting blood glucose ≥ 126 mg/dL, a self-reported physi-
cian’s diagnosis, medication use, or insulin administration
at the time of interview. Serum creatinine level was mea-
sured using a Hitachi Automatic Analyzer 7600 (Hitachi,
Japan) and a modified kinetic Jaffe reaction. The level of
kidney function was attained using an abbreviated equa-
tion developed from the data from the Chronic Kidney
Disease-Epidemiologic Collaboration Group (CKD-EPI)
study to estimate the glomerular filtration rate (GFR) [8].
We defined renal dysfunction as an estimated GFR (eGFR)
of < 65 mL/min/1.73 m2 [9]. Hypertension was defined as
having one of the following: a mean systolic blood pres-
sure of ≥ 140 mmHg, a mean diastolic blood pressure of ≥
90 mmHg, a self-reported physician’s diagnosis, or antihy-
pertensive medication use at the time of interview. Ische-
mic heart disease and stroke were based on a self-reported
physician’s diagnosis.
Other variables
Information on age, sex, residential area, educational status,
smoking exposure and alcohol consumption, occupation,
body mass index (BMI), and nutritional intake were based
on a health questionnaire. Residential area was categorized
as either urban or rural. Seoul (the capital city of South
Korea) and six other metropolitan cities were grouped as
urban areas, and the remaining regions were defined as
rural areas. Educational status was divided into ≥ college
or ≤ high school. Alcohol consumption was indicated as
positive for participants who had consumed at least 30 g
per day over the last year. The participants’ occupations
were categorized as services (which included students,
housewives, and the unemployed), agriculture, fishery, or
industry. BMI was calculated as weight in kilograms divided
by height in meters squared.
Statistical analysis
All statistical analyses and calculations were performed
using SAS V9.2 (SAS Institute). We used the stratifica-
tion variables and sampling weights designated by the
Korean Centers for Disease Control and Prevention.
The baseline characteristics were presented as mean ±
standard error (SE), median and range, or frequency and
proportions. Comparisons of each variable between the
two groups were performed using Student’s t-test or
modified Rao-Scott chi-square test. Demographic char-
acteristics were analyzed according to eGFR (< 65 or ≥
Table 1 Demographic and clinical characteristics of
participants (n = 3996)a
Characteristics % (SE)
Age, yb 45.2 ± 0.2
< 65 86.2 (0.6)





< 25 68.9 (0.9)
≥ 25 31.1 (0.9)
Smoking exposure
Never 74.3 (0.7)
Former or current 25.7 (0.7)
Alcohol drinking, g/day
< 30 90.1 (0.6)





≤ High school 70.4 (1.0)
≥ College 29.6 (1.0)
Occupation
Agriculture & fishery 5.6 (0.6)
Industry 9.2 (0.5)
Services 85.3 (0.8)
GFR, ml/min/1.73 m2b 95.1 ± 0.5
Blood pressureb
SBP, mmHg 116.9 ± 0.4
DBP, mmHg 76.7 ± 0.3
MAP, mmHg 88.7 ± 0.2
BMI = body mass index; GFR = glomerular filtration rate; SBP = systolic blood
pressure; DBP = diastolic blood pressure; MAP =mean arterial pressure.
aData are given as% (SE) unless otherwise indicated.
bData as the mean ± SE.
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(diabetes, hypertension, ischemic heart disease, or stroke),
and quartiles of blood Mn levels (first lowest quartile vs.
other quartiles). The odds ratios (OR) and 95% confidence
intervals (95% CI) of the associated factors for reduced
eGFR and blood Mn quartiles were estimated using logis-
tic regression. A p-value of < 0.05 was considered statisti-
cally significant.
Results
The total number of participants was 3996, and the
weighted number was 36,990,120. The mean participant
age was 45 ± 0.2 years. The mean blood Mn level in the
Korean adult population was 1.34 ± 0.01 μg/dL, and the
mean eGFR as calculated by the CKD-EPI equation was
95.1 ml/min/1.73 m2. The mean systolic blood, diastolic
blood, and arterial pressures were 116.9 ± 0.4 mmHg,
76.7 ± 0.3 mmHg and 88.7 ± 0.2 mmHg, respectively.
The baseline clinical characteristics of the participants
were shown in Table 1. Blood Mn levels were signifi-
cantly different in the baseline characteristics of the fol-
lowing variables: sex, smoking exposure, the history of
alcohol drinking, and residential area (data not shown).
Mn levels were also different according to the presence
of chronic disease (Table 2). Participants with diabetes
had significantly lower blood Mn levels than those with-
out diabetes (p < 0.05). Renal dysfunction and hyper-
tension presented similarly (p < 0.05). There was no
significant difference in the blood Mn levels of partici-
pants with or without ischemic heart disease or stroke.
We also evaluated the association of blood Mn level
with eGFR and blood pressure. In a linear regression
analysis adjusted for age, sex, and BMI, there was no
statistically significant association between blood Mn
levels and eGFR. However, blood Mn levels were po-
sitively associated with systolic blood (β coefficient =1.52,
p = 0.01), diastolic (β coefficient =1.01, p = 0.02), and mean
arterial blood pressures (β coefficient =1.26, p = 0.004)
after adjusting for age, sex, BMI, and presence of diabetes.
We divided blood Mn level into quartiles (Q1–Q4) and
analyzed the risk for chronic disease. In a multivariate lo-
gistic regression analysis, after adjusting for age, sex, and
BMI, participants with blood Mn levels in the higher quar-
tiles had a tendency to have lower odds ratios (OR) for the
presence of diabetes with a significant test for trend (p =
0.02; Table 3). When the higher quartiles (Q2–4, blood
Mn ≥1.060 μg/dL) were compared with the lowest quartile
(Q1, blood Mn ≤1.059 μg/dL), the OR for diabetes was
0.652 (95% CI: 0.46–0.92) and 0.589 for renal dysfunction
(95% CI: 0.39–0.88, p < 0.05) (Table 4). It was well known
that diabetes and hypertension were significant risk factors
for renal dysfunction; therefore, when adjusted for the
presence of diabetes and hypertension, the OR for renal
dysfunction was 0.617 (95% CI: 0.41–0.92, p < 0.05).The prevalence of diabetes was significantly higher in
the lowest quartile (Q1) when compared with the higher
quartiles Q2–4 (7.6% vs. 5.3%, p = 0.02). Similarly, the
prevalence of renal dysfunction showed a significantly
higher value in the lowest quartile (Q1) than in the
higher quartiles (6.8% vs. 4.6%, p = 0.02; Table 4).
Discussion
This study was the first to examine the effects of blood
Mn on chronic diseases in the general population and de-
termine that blood Mn levels affected the morbidity of
chronic diseases. It was found that low blood Mn levels
Table 2 Characteristics of participants and blood Mn levels according to the presence of chronic diseasesa






















Age (≥ 65 yrs) 39.1 (3.7) 12.2 (0.6) < .001 61.6 (4.0) 11.2 (0.5) < .001 30.8 (1.6) 7.7 (0.6) < .001 48.7 (8.8) 13.3 (0.6) < .001 42.8 (9.2) 13.5 (0.6) < .001
Sex (male) 46.0 (3.4) 49.7 (0.6) 0.31 46.4 (3.6) 49.7 (0.5) 0.38 55.0 (1.5) 47.4 (0.7) < .001 54.6 (8.0) 49.4 (0.5) 0.52 62.0 (9.4) 49.3 (0.5) 0.19
BMI (≥ 25 kg/m2) 49.7 (3.6) 29.9 (0.9) <.001 47.4 (4.2) 30.2 (0.9) < .001 46.2 (1.7) 25.8 (0.9) < .001 49.6 (8.0) 30.9 (0.9) 0.01 35.1 (8.3) 31.1 (0.9) 0.62
Smoking exposure 23.0 (2.8) 25.8 (0.8) 0.34 9.2 (2.2) 26.6 (0.8) < .001 24.9 (1.5) 26.0 (0.9) 0.54 17.3 (7.7) 25.8 (0.7) 0.92 21.3 (6.5) 25.7 (0.7) 0.53
Alcohol (≥ 30 g/day) 6.3 (1.7) 10.2 (0.6) 0.08 5.7 (1.9) 10.2 (0.6) 0.07 13.5 (1.3) 8.7 (0.6) < .001 2.1 (2.1) 10.1 (0.6) 0.07 2.8 (2.8) 10.0 (0.6) 0.16
Residence (rural) 20.6 (3.4) 20.2 (1.8) 0.89 20.9 (4.1) 20.1 (1.8) 0.83 22.2 (2.2) 19.5 (1.8) 0.07 29.2 (7.7) 20.1 (1.8) 0.17 24.0 (6.7) 20.2 (1.8) 0.54
Education (≥ college) 16.4 (2.5) 30.4 (1) < .001 9.3 (2.3) 30.7 (1.0) < .001 18.7 (1.5) 33.5 (1.1) < .001 12.1 (5.3) 29.8 (1.0) 0.02 3.7 (2.5) 29.8 (1.0) < .001
Occupation 0.02 0.93 < .001 < .001 0.95
Services & others 6.1 (1.8) 5.6 (0.6) 5.2 (1.6) 5.6 (0.6) 7.4 (1.1) 5.0 (0.6) 19.0 (7.1) 5.4 (0.6) 5.9 (3.4) 5.6 (0.6)
Industry 15.2 (3.1) 8.8 (0.5) 8.6 (2.2) 9.2 (0.5) 11.7 (1.1) 8.2 (0.6) 4.2 (2.7) 9.2 (0.5) 7.9 (4.4) 9.2 (0.5)
Agriculture & fishery 78.8 (3.4) 85.6 (0.8) 86.2 (2.7) 85.2 (0.8) 81.0 (1.5) 86.8 (0.8) 76.8 (7.3) 85.3 (0.8) 86.2 (5.3) 85.2 (0.8)
Blood Mn (μg/dL)b 1.26 ± 0.02 1.35 ± 0.01 0.001 1.28 ± 0.03 1.35 ± 0.01 0.04 1.32 ± 0.01 1.35 ± 0.01 0.04 1.25 ± 0.05 1.34 ± 0.01 0.09 1.35 ± 0.08 1.34 ± 0.01 0.94
IHD = ischemic heart disease; BMI = body mass index; Mn =Manganese.
aData are given as the percentage (SE) of each category in participants with or without chronic disease unless otherwise indicated.



















Table 3 Odds ratio and 95% confidence interval values of chronic disease presence with blood Mn level after adjusting covariates
Mn level
quartile (μg/dL)
Diabetes Renal dysfunction Hypertension IHD Stroke
Unadjusted Adjusteda Unadjusted Adjustedb Unadjusted Adjustedc Unadjusted Adjustedb Unadjusted Adjustedb
Q1 (≤ 1.059) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 (1.060 - 1.277) 0.66 (0.45, 0.97) 0.65 (0.43, 0.99) 0.52 (0.34, 0.81) 0.51 (0.31, 0.84) 1.09 (0.86, 1.37) 1.21 (0.93, 1.57) 1.03 (0.41, 2.57) 1.04 (0.38, 2.80) 0.92 (0.37, 2.30) 0.91 (0.35, 2.39)
Q3 (1.278 - 1.559) 0.86 (0.57, 1.30) 0.75 (0.49, 1.15) 0.78 (0.50, 1.20) 0.64 (0.39, 1.07) 1.15 (0.92, 1.44) 1.16 (0.90, 1.50) 1.49 (0.62, 3.59) 1.41 (0.55, 3.62) 1.22 (0.50, 3.00) 1.21 (0.48, 3.07)
Q4 (≥ 1.560) 0.53 (0.35, 0.80) 0.53 (0.34, 0.84) 0.67 (0.43, 1.05) 0.72 (0.43, 1.20) 0.86 (0.69, 1.07) 1.07 (0.83, 1.39) 0.47 (0.17, 1.36) 0.55 (0.18, 1.65) 0.94 (0.30, 2.94) 1.22 (0.39, 3.80)
P value 0.01 0.04 0.03 0.06 0.07 0.49 0.11 0.26 0.93 0.92
P for trend 0.02 0.02 0.22 0.28 0.28 0.65 0.41 0.60 0.94 0.62
IHD = ischemic heart disease; Mn =manganese.
aadjusted for age, sex, body mass index and hypertension.
badjusted for age, sex, body mass index, diabetes and hypertension.



















Table 4 Odds ratio, 95% confidence interval and prevalence of chronic diseases comparing the higher quartiles with
the lowest quartile of blood Mn level after adjusting covariates (Q1 vs Q2–4)a
Parameter Odds ratio (95% confidence interval) Prevalence (%, SE)
Unadjusted Adjusted Q1 Q2-4 P value
Diabetes 0.68 (0.50, 0.94) 0.65 (0.46, 0.92)b 7.6 (0.9) 5.3 (0.5) 0.02b
Renal dysfunction 0.65 (0.46, 0.92) 0.62 (0.41, 0.92)c 6.8 (1.0) 4.6 (0.5) 0.02c
Hypertension 1.03 (0.85, 1.24) 1.15 (0.93, 1.42)d 25.6 (1.6) 26.2 (1.0) 0.77d
IHD 1.00 (0.46, 2.16) 1.04 (0.45, 2.40)c 1.2 (0.4) 1.2 (0.2) 0.99c
Stroke 1.03 (0.48, 2.20) 1.11 (0.51, 2.42)c 0.8 (0.2) 0.8 (0.2) 0.94c
IHD = ischemic heart disease.
aBlood manganese quartiles (μg/dL): Q1 ≤ 1.059, Q2 1.060 - 1.277, Q3 1.278 - 1.559, Q4 ≥ 1.560.
badjusted for age, sex, body mass index and hypertension.
cadjusted for age, sex, body mass index, diabetes and hypertension.
dadjusted for age, sex, body mass index and diabetes.
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dysfunction, suggesting that blood Mn deficiency might
be involved in the pathophysiological processes of diabetes
and renal dysfunction.
Mn is stored primarily in skeletal bones and tissues rich
in mitochondria. However, no existing biomarker can reli-
ably determine the exact level of Mn accumulated in the
body. Because there is a discrepancy in the half-life of Mn
in the tissues and blood, Mn levels in red blood cells or
whole blood are believed to be more reliable than plasma
Mn for measuring Mn accumulation in the body [3]. For
practical reasons, whole blood samples have been used as
an exposure biomarker of Mn inhalation in most epi-
demiological studies [3] and were used accordingly in the
present study to measure blood Mn.
The importance of Mn in animals was first reported in
1931, but there has been little evidence of its deficiency in
humans [1]. In animal models, some of the abnormalities
seen in Mn deficiency relate to skeletal abnormalities,
changes in circulating HDL cholesterol, and reproductive
failure [4]. Some studies have proposed that Mn may in-
fluence high glucose conditions. A relationship between
Mn and pancreatic function was first seen in 1962 when
the blood glucose level dropped in a diabetic patient orally
administered Mn. It was postulated that Mn might accel-
erate cellular glucose uptake by potentiating insulin action
and that Mn might act on the pancreas by stimulating the
release of stored insulin into the bloodstream or by inhi-
biting the release of glucagon [10]. In addition, Baly et al.
demonstrated that Mn deficiency resulted in decreased
synthesis of pancreatic insulin, enhanced insulin degra-
dation, and lowered insulin secretion in an Mn-deficient
animal model [11]. It was also suggested that Mn defi-
ciency could affect glucose transport and metabolism in
adipose cells [12]. A recent experiment demonstrated
in vitro and in vivo that Mn2+ supplementation lowered
the risk of endothelial dysfunction in diabetes [13].
In the present study, we found a statistically significant
relationship between blood Mn levels and diabetes in arepresentative Korean population. Blood Mn levels were
lower in participants with diabetes but not in participants
with ischemic heart disease or stroke. Furthermore, the
prevalence of diabetes significantly increased in partici-
pants with blood Mn levels in the lowest quartile. The
pathophysiological mechanism of these results remained
unclear. However, the present findings were consistent
with previous reports of hypoglycemia induced by low-
dose Mn intake in diabetic patients, as well as changes
in insulin metabolism in Mn-deficient animal models
[10,11,14]. Further studies into the association of blood
Mn and insulin metabolism or glucose control status
(such as hemoglobin A1c) are needed.
Prior to this study, no clear relationship between Mn
and diabetes had been found, and the few epidemiologic
studies that addressed this issue in humans were contro-
versial. With limited comparable data, one study into the
general elderly population of the Czech Republic found no
association between blood Mn and diabetes; instead, se-
niors with atherosclerosis had higher Mn levels than those
without [15]. Three other studies linked low Mn levels with
diabetes. Kazi et al. showed that diabetic patients of both
genders in Pakistan had significantly lower blood and hair
levels of Mn than those in the controls [16]. Ekmekcioglu
et al. found decreased Mn levels in the whole blood and
erythrocytes of diabetic individuals [17]. The most recent
study revealed Mn deficiency in both type 1 and type 2 dia-
betic patients with respect to control subjects [18].
Many studies have focused on environmental Mn tox-
icity rather than on its deficiency and metabolism. Mn
toxicity in humans primarily occurs as a consequence of
chronic inhalation of high concentrations of airborne Mn-
containing particles, linking symptoms of Mn toxicity
mainly to miners as well as ferroalloy and battery manu-
facturing workers [5]. In Korea, Mn may be exposed occu-
pationally or environmentally. Typical toxicity symptoms
resemble those of idiopathic Parkinson’s disease and in-
clude tremor, rigidity, bradykinesia, and posture instability.
Patients may also display neuropsychological difficulties
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the dopaminergic systems with a neuropathology that
closely resembles Parkinson’s disease [19]. Most studies
have examined outcomes following relatively high-level
acute or chronic exposure to Mn. Less is known about
the effects of chronic exposure to lower levels of Mn or
the threshold levels sufficient for altering cognitive and
motor function [19].
Oxidative stress and inflammation play a major role in
the progression of renal damage in chronic kidney disease
(CKD). Mn is a potent antioxidant and cofactor of the en-
zyme MnSOD, which is the main antioxidant enzyme in
the mitochondria responsible for protecting the cell from
reactive oxygen species (ROS) by scavenging mitochon-
drial superoxides. Various studies using Mn2+ have linked
its effects with the function and role of MnSOD. The re-
sults in this study showed a significant association of
blood Mn level with the prevalence and risk of renal
dysfunction after adjusting for diabetes and hyperten-
sion in logistic regression analysis, although not in lin-
ear regression. Because the KNAHNES was conducted
in the general population of Koreans, we projected that
including too small a size of subjects with moderate to
advanced renal dysfunction may influence the statistical
result. Thus, we cautiously postulated that subgroups
with lower blood Mn levels may have lower MnSOD ac-
tivities, possibly making them more sensitive to oxidative
stress. Further studies are needed to verify this hypothesis.
High blood Mn levels were found, in this study, to be
consistently associated with high systolic, diastolic, and
mean arterial blood pressures after adjustment, although
no differences in the prevalence of hypertension were
found between the lower and higher blood Mn quartile
subgroups. These results may have been conflicting as
hypertension was partially dependent on self-reported data.
Nevertheless, these findings were somewhat compatible
with a previous study based on the KNHANES 2008,
which reported that blood Mn levels may have been associ-
ated with an increased risk of hypertension [20]. The study
assumed that chronic Mn accumulation in the mitochon-
dria affected MnSOD activity, resulting in an abnormal re-
sponse to the mechanism that blocked oxidative stress in
the mitochondria and protected against endothelial dys-
function. The exact pathophysiology of Mn on blood pres-
sure is unclear and remains to be elucidated.
This study had some limitations. First, it was cross-
sectional, making it difficult to establish a cause-and-
effect relationship. Diabetes appeared to have caused
lower Mn based on data showing low stores of albumin
and other binding proteins in diabetic patients [21],
suggesting that Mn and diabetes may affect each other.
Further analysis with a longer follow-up period is
needed to support the clinical importance of blood Mn
levels in diabetes. Second, our regression models were notfully adjusted for potential confounders, such as serum iron
or albumin levels, which are the main Mn-binding proteins
in the blood. Furthermore, we did not adjust for other
metals with the same valence states as Mn, including cop-
per and calcium, which may affect blood Mn levels and
other chronic diseases. There may have been participants
with chronic diseases without Mn readings, which may ex-
plain the lack of a significant association between blood
Mn levels and ischemic heart disease or stroke. Last, insuf-
ficient information was available to specify whether the dia-
betes subgroups were type I or II. Despite these limitations,
the study presented solid findings as it was performed on a
representative sample of the general Korean population
with strict quality control of the study procedures of the
KNHANES.
Conclusion
The prevalence of diabetes and renal dysfunction decreased
in participants with high blood Mn levels, suggesting that
blood Mn may have some role in glucose homeostasis and
renal function. Further studies are needed to determine any
protective effects of Mn on diabetes and renal dysfunction.
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